Geron Corporation develops therapeutics for myeloid hematologic malignancies. Imetelstat, a telomerase inhibitor, is in Phase 3 clinical trials to treat low/intermediate-1 risk MDS and intermediate-2/high-risk myelofibrosis. It inhibits the uncontrolled proliferation of malignant stem/progenitor cells. The company was incorporated in 1990 and is headquartered in California.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |